Advertisement
Canada markets open in 4 hours 47 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7332
    +0.0008 (+0.11%)
     

  • CRUDE OIL

    83.79
    +0.22 (+0.26%)
     

  • Bitcoin CAD

    87,827.91
    +751.59 (+0.86%)
     

  • CMC Crypto 200

    1,388.99
    -7.54 (-0.54%)
     

  • GOLD FUTURES

    2,359.10
    +16.60 (+0.71%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,757.50
    +190.00 (+1.08%)
     

  • VOLATILITY

    15.53
    +0.16 (+1.04%)
     

  • FTSE

    8,107.55
    +28.69 (+0.36%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6818
    -0.0003 (-0.04%)
     

Pfizer and BioNTech's Coronavirus Vaccine Ready for Regulatory Submission in December, Maybe Earlier

Brian Orelli, PhD, The Motley Fool
·2 min read
Pfizer and BioNTech's Coronavirus Vaccine Ready for Regulatory Submission in December, Maybe Earlier

BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE) are right on the heels of Moderna (NASDAQ: MRNA) in the race to potentially develop a messenger RNA (mRNA) vaccine against SARS-CoV-2, the novel coronavirus that causes COVID-19. In an interview with The Wall Street Journal, BioNTech CEO Ugur Sahin predicted the companies will have enough data for a vaccine to be ready for approval by December. The companies are still trying to figure out which of multiple vaccine candidates should be taken into a 30,000-patient phase 2/3 clinical trial that is scheduled to start this month.

Continue reading